Stifling regulations are preventing China’s 1.4 billion people from accessing several common vaccines available in much of the rest of the world, raising public health risks and posing a challenge to global pharmaceutical companies in a huge potential market.
Sam Ding, a tech professional in southern China, says he crossed the border to Hong Kong twice to get his one-year-old daughter a key vaccine for potentially fatal conditions -- pneumonia, blood infections and meningitis.
